NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS

Why it matters

A blood-based biomarker that tracks treatment response in ALS could give drug developers a faster, less invasive way to measure whether therapies are working, potentially accelerating clinical trial timelines industry-wide.